Results from RATIONALE 303

 PDF   18   05/2021

Results from RATIONALE 303: A global phase 3 study of tislelizumab vs docetaxel as second or third line therapy for patients with locally advanced or metastatic NSCLC

Clinical presentation by Yiyuan Ma, M.D.

Rating

Rate this resource

Nice to see you!

For newest details on our EHA materials in a personal video meeting, please click here!
Service